Fibrodysplasia ossificans progressiva: a case report.
DOI:
https://doi.org/10.35954/SM2015.34.2.7Keywords:
Fibrodysplasia ossificans progressiva; Myositis ossificansAbstract
The clinical case of a 15-year-old female patient with congenital malformations of the hands and feet (brachydactyly) and hyperlaxity is described. She is diagnosed with fibrodysplasia ossificans progressiva: it is accompanied by characteristic bone anomalies: shortening of the first toe of both feet due to alterations of the phalanges, the proximal one may be suppressed or there may be synostosis of the same resulting in hallux valgus which becomes more evident than the shortening. The disease presents a relentlessly progressive course.
Downloads
Metrics
References
(1) Jaeger Helmut W. Miositis osificante múltiple progresiva o enfermedad de Munchmeyer. Rev Chil Ped 1942; 13(9):785-803.
(2) Federación ASEM. Fibrodisplasia Osifícante Progresiva. Disponible en: http://www.asem-esp.org/index.php/tipos-de-enm#mop8 [Consulta 31/07/2015].
(3) Feldman G, Li M, Martin S, Urbanek M, Urtizberea A, Fardeau M, et al. Fibrodysplasia Ossificans Progressiva, a heritable disorder of severe heterotopic ossification, maps to human chromosome 4q27-31. Am J Human Genet 2000; 66(1):128-135.
(4) Kaplan F, Shore E, Connor J. Fibrodysplasia ossificans progressiva (FOP). In: Royce P, Steinmann B (eds). Connective Tissue and Its Heritable Disorders. New York : Wiley-Liss, 2002, 827-840.
(5) Shafritz A, Shore E, Gannon F, Zasloff M, Taub R, Muenke M, et al. Overexpression of an osteogenic morphogen in fibrodysplasia ossificans progressive. N Engl J Med 1996; 335(8):555-61.
(6) Shore E, Xu M, Shah P, Janoff H, Hahn G, Deardorff M, et al. The human bone morphogenetic protein (BMP4) gene: molecular structure and transcriptional regulation. Calcif Tissue Int 1998; 63(3):221-9.
(7) Cleaves Fransisco Rivera Medina M, Alvarenga Colidomio R. Fibrodisplasia Osificante Progresiva. A propósito de un caso. Honduras Pediátrica 2001; XXII (1):18-21.
(8) Kaplan F. Inmunization in children with FOP.Do`S, don't´s and dilemas. Online guidebook. IFOPA University of Pensylvania Health System. Disponible en: htp///www.med.upenn.edu [Consulta 31/06/2015]
(9) Brantus J, Meunier P. Effects of intravenous etinodrnate and oral corticosteroids in fibrodysplasia ossifican progresiva. Clin Orthop Relat Res 1998; 346:117-20.
(10) Kaplan F, Shore E, Glaser D, Emerson S. The Medical Management of Fibrodysplasia Ossificans Progressiva: current treatment considerations. Clin Proc intl clin consort FOP2011; 4:1-100.
(11) International Fibrodysplasia Ossificans Progressiva Associations. Disponible en: http://www.ifopa.org [Consulta 31/06/2015]
Published
How to Cite
Issue
Section
License
Until 2024 we use the Creative Commons Attribution/NonCommercial Attribution 4.0 International License https://creativecommons.org/licenses/by-nc/4.0/deed.es. Which states that: you are free to share, copy and redistribute the material in any medium or format, as well as to adapt, remix, transform and build upon the material. Under the following terms:
Attribution: you must give proper credit , provide a link to the license, and indicate if changes have been made . You may do so in any reasonable manner, but not in such a way as to suggest that you or your use is endorsed by the licensor.
NonCommercial: you may not use the material for commercial purposes.
As of 2025 authors retain their copyright and assign to the journal the right of first publication of their work, which shall simultaneously be subject to the license https://creativecommons.org/licenses/by-nc-sa/4.0/deed.es that permits sharing, copying and redistribution of the material in any medium or format provided that initial publication in this journal is indicated. Adapt, remix, transform and build upon the material. If you remix, transform, or build from the material, you must distribute your contribution under the same license as the original and may not make use of the material for commercial purposes.
Under the following terms:
1. Attribution: you must give proper credit, provide a link to the license, and indicate whether changes have been made. You may do so in any reasonable manner, but not in such a way as to suggest that you or your use is endorsed by the licensor.
2. NonCommercial: you may not use the material for commercial purposes.
3. ShareAlike: if you remix, transform or build upon the material, you must distribute your contribution under the same license as the original.
PlumX Metrics
/
